jmp version 11.0 for windows (SAS institute)
SAS institute is a verified supplier 
90
Structured Review
SAS institute
jmp version 11.0 for windows
Jmp Version 11.0 For Windows, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/jmp+version+11%2E0+for+windows/jmp+version+11+0/pmc12046617-85-6-11
Average 90 stars, based on 1 article reviews
Jmp Version 11.0 For Windows, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/jmp+version+11%2E0+for+windows/jmp+version+11+0/pmc12046617-85-6-11
Average 90 stars, based on 1 article reviews
jmp version 11.0 for windows - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Post‐progression survival is highly linked to overall survival in patients with non‐small‐cell lung cancer harboring sensitive EGFR mutations treated with first‐line epidermal growth factor receptor‐tyrosine kinase inhibitors Article Snippet: All statistical analyzes were conducted using JMP, version 11.0, for Article Title: Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival Article Snippet: Article Title: Clinical significance of post‑progression survival after chemoradiotherapy on overall survival in limited‑disease small cell lung cancer Article Snippet: All statistical analyses were performed using Article Title: Correlation of Fecal Markers with Magnifying Endoscopic Stratification in Patients with Ulcerative Colitis Who Are in Clinical Remission. Article Snippet: Statistical Analyses Statistical analyses were performed using Article Title: Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. Article Snippet: Purpose Immune checkpoint inhibitors (ICIs) are an effective subsequent-line treatment for patients with advanced non-small cell lung cancer (NSCLC).. However, it remains unclear whether the efficacy and safety of subsequent-line ICI monotherapy in elderly patients (aged ≥ 75 years) are similar to that in non-elderly patients.. Therefore, we aimed to investigate the efficacy and safety of ICI monotherapy in pretreated elderly patients with NSCLC. Article Title: Efficacy and safety of naldemedine for opioid-induced constipation in older patients with cancer: a retrospective study Article Snippet: All statistical analyses were performed using Article Title: Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. Article Snippet: Purpose Pembrolizumab is an effective front-line treatment for advanced non-small cell lung cancer (NSCLC) in patients expressing high levels of programmed death-ligand 1 (PD-L1).. However, it is unclear whether first-line pembrolizumab has similar efficacy among elderly (aged ≥ 75 years) and younger patients.. This study aimed to investigate the safety and efficacy of front-line pembrolizumab monotherapy in older adults with NSCLC expressing high PD-L1. Article Title: Efficacy and safety of S ‐1 monotherapy in previously treated elderly patients (aged ≥75 years) with non‐small cell lung cancer: A retrospective analysis Article Snippet: All statistical analyses were conducted using the |